6wv5
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Human VKOR C43S mutant with vitamin K1 epoxide== | ==Human VKOR C43S mutant with vitamin K1 epoxide== | ||
| - | <StructureSection load='6wv5' size='340' side='right'caption='[[6wv5]]' scene=''> | + | <StructureSection load='6wv5' size='340' side='right'caption='[[6wv5]], [[Resolution|resolution]] 2.80Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WV5 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6WV5 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6wv5]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Aeqvi Aeqvi]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WV5 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6WV5 FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6wv5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wv5 OCA], [http://pdbe.org/6wv5 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6wv5 RCSB], [http://www.ebi.ac.uk/pdbsum/6wv5 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6wv5 ProSAT]</span></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=UAV:(2R,3R)-2-hydroxy-3-methyl-2-[(2E,7S)-3,7,11,15-tetramethylhexadec-2-en-1-yl]-2,3-dihydronaphthalene-1,4-dione'>UAV</scene></td></tr> |
| + | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=CRO:{2-[(1R,2R)-1-AMINO-2-HYDROXYPROPYL]-4-(4-HYDROXYBENZYLIDENE)-5-OXO-4,5-DIHYDRO-1H-IMIDAZOL-1-YL}ACETIC+ACID'>CRO</scene></td></tr> | ||
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">gfp ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=6100 AEQVI])</td></tr> | ||
| + | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Oxidoreductase Oxidoreductase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.17.4.4 1.17.4.4] </span></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6wv5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wv5 OCA], [http://pdbe.org/6wv5 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6wv5 RCSB], [http://www.ebi.ac.uk/pdbsum/6wv5 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6wv5 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Vitamin K antagonists are widely used anticoagulants targeting vitamin K epoxide reductases (VKOR), a family of integral membrane enzymes. To elucidate their catalytic cycle and inhibitory mechanism, here we report eleven x-ray crystal structures of human VKOR and pufferfish VKOR-like with substrates and antagonists in different redox states. Substrates entering the active site in a partially oxidized state form a cysteine adduct that induces an open-to-closed conformational change, triggering reduction. Binding and catalysis is facilitated by hydrogen-bonding interactions in a hydrophobic pocket. The antagonists bind specifically to the same hydrogen-bonding residues and induce a similar closed conformation. Thus, vitamin K antagonists act through mimicking the key interactions and conformational changes required for the VKOR catalytic cycle. | ||
| + | |||
| + | Structural basis of antagonizing the vitamin K catalytic cycle for anticoagulation.,Liu S, Li S, Shen G, Sukumar N, Krezel AM, Li W Science. 2020 Nov 5. pii: science.abc5667. doi: 10.1126/science.abc5667. PMID:33154105<ref>PMID:33154105</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6wv5" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Aeqvi]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Li W]] | + | [[Category: Oxidoreductase]] |
| - | [[Category: Liu S]] | + | [[Category: Li, W]] |
| - | [[Category: Sukumar N]] | + | [[Category: Liu, S]] |
| + | [[Category: Sukumar, N]] | ||
| + | [[Category: Fluorescent protein]] | ||
| + | [[Category: Membrane protein]] | ||
| + | [[Category: Superwarfarin]] | ||
| + | [[Category: Vitamin k]] | ||
| + | [[Category: Warfarin]] | ||
Revision as of 07:10, 25 November 2020
Human VKOR C43S mutant with vitamin K1 epoxide
| |||||||||||
